BMO
TEVA icon

Beck Mack & Oliver’s Teva Pharmaceuticals TEVA Stock Holding History

Beck Mack & Oliver’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.7M Sell
1,051,700
-4,800
-0.5% -$154K 0.65% 37
2025
Q4 		$33M Sell
1,056,500
-40,480
-4% -$997K 0.6% 37
2025
Q3 		$22.2M Sell
1,096,980
-2,005
-0.2% -$35.2K 0.4% 43
2025
Q2 		$18.4M Sell
1,098,985
-71,750
-6% -$1.16M 0.35% 45
2025
Q1 		$18M Sell
1,170,735
-26,755
-2% -$478K 0.36% 45
2024
Q4 		$26.4M Sell
1,197,490
-36,160
-3% -$658K 0.49% 42
2024
Q3 		$22.2M Sell
1,233,650
-73,650
-6% -$1.29M 0.43% 42
2024
Q2 		$21.2M Sell
1,307,300
-586,191
-31% -$9.03M 0.44% 43
2024
Q1 		$26.7M Sell
1,893,491
-538,723
-22% -$6.79M 0.54% 39
2023
Q4 		$25.4M Sell
2,432,214
-744,898
-23% -$6.95M 0.59% 40
2023
Q3 		$32.4M Sell
3,177,112
-560,574
-15% -$5.22M 0.85% 36
2023
Q2 		$28.1M Sell
3,737,686
-1,957,972
-34% -$15.9M 0.74% 37
2023
Q1 		$50.4M Sell
5,695,658
-668,675
-11% -$6.61M 1.46% 26
2022
Q4 		$58M Sell
6,364,333
-1,172,652
-16% -$10.2M 1.7% 21
2022
Q3 		$60.8M Buy
7,536,985
+1,072,190
+17% +$9.48M 1.96% 16
2022
Q2 		$48.6M Buy
6,464,795
+134,375
+2% +$1.17M 1.46% 24
2022
Q1 		$59.4M Buy
6,330,420
+842,157
+15% +$7.03M 1.49% 24
2021
Q4 		$44M Sell
5,488,263
-1,876,403
-25% -$16.9M 1.05% 35
2021
Q3 		$71.7M Buy
7,364,666
+2,919,985
+66% +$27.3M 1.86% 18
2021
Q2 		$44M Buy
4,444,681
+354,822
+9% +$3.76M 1.17% 33
2021
Q1 		$47.2M Buy
4,089,859
+180,493
+5% +$2.07M 1.46% 27
2020
Q4 		$37.7M Sell
3,909,366
-171,060
-4% -$1.64M 1.25% 30
2020
Q3 		$36.8M Buy
4,080,426
+82,726
+2% +$875K 1.35% 27
2020
Q2 		$49.3M Buy
3,997,700
+36,517
+0.9% +$413K 1.83% 17
2020
Q1 		$35.6M Buy
3,961,183
+1,007,043
+34% +$10.3M 1.58% 21
2019
Q4 		$29M Buy
2,954,140
+540,718
+22% +$4.83M 0.96% 32
2019
Q3 		$16.6M Buy
2,413,422
+645,645
+37% +$4.95M 0.58% 44
2019
Q2 		$16.3M Sell
1,767,777
-2,398,062
-58% -$28.9M 0.57% 42
2019
Q1 		$65.3M Buy
4,165,839
+678,967
+19% +$12M 2.34% 13
2018
Q4 		$53.8M Buy
3,486,872
+493,167
+16% +$10.1M 2.16% 15
2018
Q3 		$64.5M Buy
+2,993,705
New +$69.5M 2.05% 18
2015
Q4 		– Sell
-24,272
Closed -$1.37M – 318
2015
Q3 		$1.37M Sell
24,272
-1,675
-6% -$109K 0.04% 141
2015
Q2 		$1.53M Hold
25,947
– – 0.04% 138
2015
Q1 		$1.62M Hold
25,947
– – 0.04% 141
2014
Q4 		$1.49M Buy
25,947
+22
+0.1% +$1.23K 0.04% 144
2014
Q3 		$1.39M Buy
25,925
+250
+1% +$13.2K 0.03% 153
2014
Q2 		$1.35M Sell
25,675
-1,864
-7% -$95.3K 0.03% 152
2014
Q1 		$1.46M Hold
27,539
– – 0.03% 144
2013
Q4 		$1.1M Sell
27,539
-100
-0.4% -$3.94K 0.03% 172
2013
Q3 		$1.04M Sell
27,639
-3,600
-12% -$140K 0.03% 168
2013
Q2 		$1.22M Buy
+31,239
New +$1.22M 0.03% 163

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beck Mack & Oliver's TEVA Position: Q1 2026 in Review

Beck Mack & Oliver reduced its Teva Pharmaceuticals (TEVA) stake by 0.45% in Q1 2026, selling an estimated $154K and leaving 1,051,700 shares worth $31.7M. The position accounts for 0.65% of the portfolio, ranked #37.

Beck Mack & Oliver first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $71.7M in Q3 2021. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Beck Mack & Oliver held 1,051,700 shares of Teva Pharmaceuticals worth $31.7M as of Q1 2026.
  • Beck Mack & Oliver sold 4,800 Teva Pharmaceuticals shares in Q1 2026, an estimated $154K.
  • Teva Pharmaceuticals made up 0.65% of Beck Mack & Oliver's portfolio in Q1 2026, its #37 holding.
  • Beck Mack & Oliver first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • Beck Mack & Oliver's Teva Pharmaceuticals position peaked at $71.7M in Q3 2021.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Beck Mack & Oliver's 13F filing for Q1 2026, filed 12 May 2026.